Grail Inc. (NASDAQ:GRAL) saw a 379.5 percent surge in 2025, driven by positive analyst ratings and confidence in its Galleri cancer detection test kit. The kit screens for over 50 types of cancer and showed a positive predictive value of 61.6 percent in clinical trials.

Samsung has partnered with Grail Inc. for exclusive distribution of the Galleri test kit in key Asian markets, including South Korea, Japan, and Singapore. Analysts have issued optimistic coverage on GRAL, with price targets raised to $105 and $110. The company aims for FDA approval in Q1 2026 for Galleri.

Read more at Yahoo Finance: Grail Inc (GRAL) Climbs 380% on Strong Optimism for Cancer Detection Kit